Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase

Abstract

Fluoropyrimidines are widely used in the treatment of solid tumors, mainly gastrointestinal, head and neck and breast cancer. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme for catabolism of 5-FU and it is encoded by DPYD gene. To date, many known polymorphisms cause DPD deficiency and subsequent increase of 5-FU toxicity. In addition, reduced inactivation of 5-FU could lead to increased 5-FU intracellular concentration and augmented efficacy of this drugs. Therefore DPD expression, particularly intratumoral, has been investigated as predictive and prognostic marker in 5-FU treated patients. There also seems to be a tendency to support the correlation between DPD expression and response/survival in patients treated with fluoropyrimidine even if definitive conclusions cannot be drawn considering that some studies are conflicting. Therefore, the debate on intratumoral DPD expression as a potential predictor and prognostic marker in patients treated with fluoropyrimidines is still open. Four DPD-polymorphisms are the most relevant for their frequency in population and clinical relevance. Many studies demonstrate that treating a carrier of one of these polymorphisms with a full dose of fluoropyrimidine can expose patient to a severe, even life-threatening, toxicity. Severe toxicity is reduced if this kind of patients received a dose-adjustment after being genotyped. CPIC (Clinical Pharmacogenetics Implementation Consortium) is an International Consortium creating guidelines for facilitating use of pharmacogenetic tests for patient care and helps clinicians ensuring a safer drug delivery to the patient. Using predictive DPD deficiency tests in patients receiving 5FU-based chemotherapy, in particular for colorectal cancer, has proven to be a cost-effective strategy.

Keywords

5-fluorouracil / fluoropyrimidines / chemotherapy / dihydropyrimidine dehydrogenase / dihydropyrimidine dehydrogenase / DPYD / CPIC / polymorphisms

References

[1] Ezzeldin H.Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration..Clin Colorectal Cancer2004;4:181-9

[2] Scrip’s Cancer Chemotherapy Report. Scrip World Pharmaceutical News.2002;LondonPJB Publications Ltd

[3] Loriot MA,Thomas F,Royer B.Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks..Bull Cancer2018;105:397-407

[4] Heggie GD,Cross DS,Diasio RB.Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile..Cancer Res1987;47:2203-6

[5] Van Cutsem E,Cassidy J,Bajetta E.Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study..J Clin Oncol2001;19:4097-106

[6] Rosmarin D,Pagnamenta A,Pita G.A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS..Gut2015;64:111-20 PMCID:PMC4283622

[7] Saltz LB,Hollis D,Hantel A.Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803..J Clin Oncol2007;25:3456-61

[8] Harris BE,Soong SJ.Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion..Cancer Res1990;50:197-201

[9] Grem JL,Venzon D,Allegra CJ.Inter- and intra-individual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells..Cancer Chemother Pharmacol1997;40:117-25

[10] Ogura K,Minamide Y,Nishiyama A.Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations..Clin Cancer Res2005;11:5104-111

[11] Morsman JM,Ameyaw MM,Indalo A.Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations..Br J Clin Pharmacol2000;50:269-72 PMCID:PMC2014976

[12] Yamaguchi K,Kanda Y.Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-fluorouracil..Jpn J Cancer Res2001;92:337-42 PMCID:PMC5926718

[13] Diasio RB.Clinical pharmacology of 5-fluorouracil..Clin Pharmacokinet1989;16:215-37

[14] Longley DB,Johnston PG.5-fluorouracil: mechanisms of action and clinical strategies..Nat Rev Cancer2003;3:330-8

[15] Johnson MR.Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil..Adv Enzyme Regul2001;41:151-7

[16] Mattison LK,Desmond RA,Saif MW.Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians..Clin Cancer Res2006;12:5491-5

[17] Lu Z,Diasio RB.Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy..Cancer Res1993;53:5433-8

[18] Etienne MC,Dassonville O,Thyss A.Population study of dihydropyrimidine dehydrogenase in cancer patients..J ClinOncol1994;12:2248-53

[19] Amstutz U,Largiadèr CR.Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity..Pharmacogenomics2011;12:1321-36

[20] Morel A,Fey L,Craipeau MC.Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance..Mol Cancer Ther2006;5:2895-904

[21] Van Kuilenburg AB,Richel DJ,Van Lenthe H.Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene..Clin Cancer Res2000;6:4705-12

[22] Milano G,Pierrefite V,Deporte-Fety R.Dihydropyrimidine dehydrogenase deficiency and fluorouracilrelated toxicity..Br J Cancer1999;79:627-30 PMCID:PMC2362417

[23] Van Kuilenburg AB,Zoetekouw L.Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G>A mutation..Int J Cancer2002;101:253-8

[24] Wei X,Sapone A,Raunio H.Characterization of the human dihydropyrimidine dehydrogenase gene..Genomics1998;51:391-400

[25] Offer SM.Is it finally time for a personalized medicine approach for fluorouracil-based therapies?.J Clin Oncol2016;34:205-7

[26] Deenen MJ,Cats A,Severens JL.Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis..J Clin Oncol2016;34:227-34

[27] Launay M,Rodallec A,Duffaud F.Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 - Where Do We Stand?.Clin Cancer Drugs2017;4:74-81

[28] Siddiqui NS,Hamal R,Diasio RB.Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades..J Clin Oncol2018;36:2576

[29] Van Staveren MC,Van Kuilenburg ABP,Maring JG.Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency..Pharmacogenomics J2013;13:389-95

[30] Launay M,Duval M,Milano G.Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer..Br J Clin Pharmacol2016;81:124-30 PMCID:PMC4693577

[31] Amstutz U,Offer SM,Schellens JHM.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update..Clin Pharmacol Ther2018;103:210-6 PMCID:PMC5760397

[32] Lee AM,Pavey E,Sargent DJ.DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)..J Natl Cancer Inst2014;106:1-12 PMCID:PMC4271081

[33] Meulendijks D,Beijnen JH.Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - ready for clinical practice?.Cancer Treat Rev2016;50:23-34

[34] Henricks LM,Meulendijks D,Cats A.Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score..Pharmacogenomics2015;16:1277-86

[35] Van Kuilenburg AB,Haasjes J,Zoetekouw L.Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G>A mutation causing DPD deficiency..Clin Cancer Res2001;7:1149-53

[36] Van Kuilenburg AB,Beex LV,Van Lenthe H.Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity..Eur J Cancer1997;33:2258-64

[37] Offer SM,Fossum C,Diasio RB.Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity..Cancer Res2013;73:1958-68 PMCID:PMC3602211

[38] Johnson MR,Wang K,Smith JB.Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil..Clin Cancer Res1999;5:2006-11

[39] Seck K,Kates R,Lutz V.Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals..Clin Cancer Res2005;11:5886-92

[40] Caudle KE,Klein TE,McLeod HL.Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing..Clin Pharmacol Ther2013;94:640-5 PMCID:PMC3831181

[41] Offer SM,Wegner NJ,Butterfield GL.Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity..Cancer Res2014;74:2545-54 PMCID:PMC4012613

[42] Amstutz U,Aebi S.Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment..Pharmacogenomics2009;10:931-44

[43] Van Kuilenburg AB,Mul AN,Schmid V.Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity..Hum Genet2010;128:529-38 PMCID:PMC2955237

[44] Deenen MJ,Burylo AM,de Boer A.Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer..Clin Cancer Res2011;17:3455-68

[45] Froehlich TK,Aebi S,Largiadèr CR.Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity..Int J Cancer2015;136:730-9

[46] Sistonen J,Froehlich TK,Fontana S.Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio..Pharmacogenomics2014;15:1653-66

[47] Meulendijks D,van Kuilenburg AB,Aliev A.Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines..Cancer Chemother Pharmacol2016;78:875-80

[48] Meulendijks D,Sonke GS,Froehlich TK.Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data..Lancet Oncol2015;16:1639-50

[49] Henricks LM,Beijnen JH,Schellens JHM.DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update..Ann Oncol2017;28:2915-22

[50] Henricks LM,de Man FM,Frederix GWJ.DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis..Lancet Oncol2018;19:1459-67

[51] Vallböhmer D,Kuramochi H,Danenberg KD.DPD is a molecular determinant of capecitabine efficacy in colorectal cancer..Int J Oncol2007;31:413-8

[52] Salonga D,Johnson M,Groshen S.Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase..Clin Cancer Res2000;6:1322-7

[53] Yanagisawa Y,Iinuma N,Koide N.Modified irinotecan/5FU/leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumorrelated enzymes..Scand J Gastroenterol2007;42:477-84

[54] Meropol NJ,Diasio RB,Dhami M.Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer..J Clin Oncol2006;24:4051-3

[55] Koopman M,Tinteren H,Nagtegaal I.Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the Phase III randomised CAIRO study..Eur J Cancer2009;45:1999-2006

[56] Gustavsson B,Carlsson G,Odin E.Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes..Int J Cancer2009;124:1220-6

[57] Ciaparrone M,Schinzari G,Corsi DC.Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil..Oncology2006;70:366-77

[58] Oi K,Ozaki M,Yamane N.Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes’ C colorectal cancer..Anticancer Res2004;24:273-9

[59] Lassmann S,Rosenberg R,Vannozzi F.Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up..Int J Colorectal Dis2006;21:238-47

[60] Hotta T,Taniguchi K,Yokoyama S.The relationship between survival and the expression of dihydropyrimidine dehydrogenase in patients with colorectal cancer..Oncol Rep2006;16:177-82

[61] Jensen SA,Sorensen JB.The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil..Int J Cancer2007;120:694-701

[62] Soong R,Salto-Tellez M,Soo RA.Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy..Ann Oncol2008;19:915-9 PMCID:PMC2931808

[63] Kornmann M,Sander S,Sträter J.Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil..Clin Cancer Res2003;9:4116-24

[64] Westra JL,Schaapveld M,Oien KA.Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients..Ann Oncol2005;16:1646-53

[65] Kornmann M,Galuba I,Schwabe W.Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer..J Gastrointest Surg2002;6:331-7

[66] IKeguchi M,Kaibara N.Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis..Langenbecks Arch Surg2002;387:240-5

[67] Smorenburg CH,Van Groeningen CJ,Smid K.Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase..Ann Oncol2006;17:35-42

[68] Toriumi F,Saikawa Y,Otani Y.Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma..Anticancer Res2004;24:2455-63

[69] Terashima M,Fujiwara H,Takagane A.Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer..Anticancer Res2002;22:761-8

[70] Park JS,Kim JM,Kim YS.Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray..Cancer Lett2004;214:19-33

[71] Ishikawa Y,Otani Y,Teramoto T.Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil..Jpn J Cancer Res2000;91:105-112 PMCID:PMC5926227

[72] Kodera Y,Fujiwara M,Nakayama G.Gene expression of 5- fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5- fluorouracil..Cancer Lett2007;252:307-13

[73] Nishina T,Miyaike J,Suzuki S.The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine..Eur J Cancer2004;40:1566-71

[74] Koizumi W,Hyodo I,Kojima H.Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase..Anticancer Drugs2008;19:819-24

[75] Shimizu T,Yasui H,Fukuoka M.Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine..Anticancer Res2005;25:2997-3001

[76] Ichikawa W,Suto K,Nihei Z.Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1..Int J Cancer2006;119:1927-33

[77] Kim JY,Kim JW,Lee DW.Impact of intratumoral expression levels of fluoropyrimidine-Metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer..PloS One2015;10:e0120324 PMCID:PMC4368508

[78] Sasako M,Ichikawa W,Kitada K.Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival instage II/III gastric cancer..Gastric Cancer2015;18:538-48 PMCID:PMC4511074

[79] Grau JJ,Monzò M,Domingo-Domenech J.Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy..J Surg Oncol2008;98:130-4

[80] Matsubara J,Yamada Y,Shimoda T.Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer..Brit J Cancer2008;98:832-9 PMCID:PMC2259181

[81] Shen XM,Lian L,Li W.Relationship between the DPD and TS mRNA expression and the response to S-1-based chemotherapy and prognosis in patients with advanced gastric cancer..Cell Biochem Biophys2015;71:1653-61

[82] Koizumi W,Azuma M,Nishimura K.Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer..Int J Cancer2010;126:162-70

[83] Tahara M,Fujimoto J,Yasui W.Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5fluorouracil..Oncology Rep2004;11:9-15

[84] Zhang C,Ma B,Gao P.The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis..Dis Markers2017;3:1-11 PMCID:PMC5307138

[85] Kondo N,Uemura K,Hashimoto Y.Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection..J Surg Oncol2011;104:146-54

[86] Elander NO,Ghaneh P,Palmer DH.Expression of dihydropirimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer..Brit J Cancer2018;118:947-54 PMCID:PMC5931115

[87] Nakahara O,Tanaka H,Ikuta Y.Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer..Int J Clin Oncol2010;15:39-45

[88] Murakawa M,Miyagi Y,Kazama K.Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy..Oncol Lett2017;14:1505-11 PMCID:PMC5529930

[89] Miyake K,Yoshizumi T,Morine Y.Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinico pathological features of patients with pancreatic cancer..Int J Clin Oncol2007;12:111-9

[90] Saif MW,Bell D.Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival..Expert Opin Drug Saf2009;8:507-514

[91] Etienne MC,Fischel JL,Dassonville O.Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity..J Clin Oncol1995;13:1663-70

[92] Tsuzuki M,Chiba H.Clinical significance of exression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma..Oral Med Path2010;14:135-41

[93] Hasegawa Y,Hanai N,Hirakawa H.Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hipopharyngeal cancers..Mol Clin Oncol2018;8:378-86 PMCID:PMC5774537

[94] Yu Z,Sun J.Dihydropirimidine dehydrogenase activity correlates with fluorouracil sensitivity in breast cancer..Exp Oncol2007;29:192-6

[95] Horiguchi J,Koibuchi Y,Ninomiya J.Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer..Br J Cancer2002;86:222-5 PMCID:PMC2375185

[96] Hakamada Y,Arima M,Tokita H.Prognostic predictors in breast cancer patients with postoperative 5-fluorouracil-based chemotherapy..Int J Mol Med2005;16:309-14

[97] Tsunoda Y,Tsunoda A,Kusano M.Evaluation of 5-fluorouracil related genes in breast cancer to predict the effect of adjuvant therapy with oral fluorouracil derivatives..Oncol Rep2010;23:771-7

[98] Zhao H,Hu Z,Lin SX.Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy..Anticancer Drugs2012;23:534-42

[99] Qin F,Huang Y,Yu F.Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy..Oncotarget2017;8:112060-75 PMCID:PMC5762379

[100] Huang CL,Kobayashi S,Hitomi S.Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy..Int J Oncol2000;17:47-54

[101] Okuda K,Yano M,Yamada T.The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross-complementation group 1 and class III β-tubulin, and the therapeutic effect of S-1 or carboplatin plus paclitaxel in non-small-cell lung cancer..Mol Clin Onc2018;9:21-9 PMCID:PMC6031014

[102] Clinical Pharmacogenetics Implemetation Consortium. Available from https://cpicpgx.org/ [Last accessed on 18 Jun 2019]

[103] Lunenburg CA,Gelderblom H,Swen JJ.Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients..Pharmacogenomics2016;17:721-9

[104] Opdam FL,Wessels JA.SNPs and haplotypes inDPYD and outcome of capecitabine—letter..Clin Cancer Res2011;17:5837

[105] Rosmarin D,Church D,Jones A.Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis..J Clin Oncol2014;32:1031-9 PMCID:PMC4879695

[106] Murphy C,Ahmed G,Gallagher J.Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience..Dose Response2018;16:1-6 PMCID:PMC6168732

[107] Traorè S,Hunault G,Morel A.DPD deficiency: medicoeconomic evaluation of pretreatment screening of 5-FU toxicity..J Clin Oncol2012;30:410

[108] Scartozzi M,Giampieri R,Bittoni A.5-Fluorouracil pharmacogenomics: still rocking after all these years?.Pharmacogenomics2011;12:251-65